Venn Life Sciences Holdings plc

Offer details

Expected size of offer (M):	�2.5m
Expected first date of trading:	14/12/2012
Market:	AIM
Location of address at which admission document will be available:	Venn Life Sciences Holdings Plc, 14 Kinnerton Place South, London SW1X 8EH Zeus Capital Limited, 3 Ralli Courts, West Riverside, Manchester M3 5FT www.vennlifesciences.com
Date at which admission document will be available:	-

Advisors

Sponsor:	-
Nominated Advisor (AIM Companies):	Zeus Capital Limited
Nominated Broker (AIM Companies):	Zeus Capital Limited
Financial PR Advisors:	-

Company details

Name	Role
David Eric Evans	Non Executive Chairman
Anthony (Tony) Francis Richardson	Chief Executive Officer
Paul Andrew Peter Foulger	Finance Director
Michael (Mike) Ryan	Non Executive Director

Facts and Figures

Fiscal year end:	31 December
Incorporated in:	UK
Website URL:	www.vennlifesciences.com

Description of business:
Venn Life Sciences Holdings plc's wholly owned subsidiaries operate two types of business: - a CRO (Contract Research Organisation) business that provides clinical trial management and performance services, to pharmaceutical, medical device and biotechnology companies; and - a clinical resourcing business that supplies clinical staff to organisations that require additional resources...

Person(s) interested:
Name As at the date of this Admission Document (%) Immediately Following Admission (%) Helium Special Situations Fund Ltd 15.38 1.66 Rathbone Brothers Plc 13.85 1.49 Richard Hughes 10.00 1.08 Hawk Investment Holdings Ltd 7.69 0.83 Nick Mustoe 7.69 0.83 Glynn Hirsch 7.69 0.83 Paul Foulger 1 6.92 1.74 Adam Reynolds 2 6.92 1.08 JM Finn & Co 4.62 0.50 Zeus Capital Ltd 3.85 0.41 Hub Capital Partners Ltd 2 3.85 0.41 Daron Lee 3.08 0.33 Laura Deegan 1 3.08 0.33 David Newton 0 12.52 William Fleming Approved Retirement Fund 0 8.50 (1) Laura Deegan is a related party of Paul Foulger as his partner. (2) Adam Reynolds is interested in 12.9% of the issued share capital of Hub Capital Partners.